UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 22nd, 2016
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its
charter)
Nevada |
333-192759 |
20-3373669 |
(State of incorporation) |
(Commission File Number) |
(IRS Employer No.) |
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices and
Zip Code)
877 424-2429
(Registrant's telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a -12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d -2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e -4(c))
Item 1.01 Entry into a Material Definitive Agreement
On October 7th,
2015, Cannabics Pharmaceuticals Inc. (the “Issuer”) executed an Intellectual Property & Subsidiary Assignment and
an Assignment & Assumption of Debt & Liabilities Agreement with Cannabics, Inc., a Delaware Corporation, related party,
and majority holder of the Issuer, as noted in the 8-K of that date. Said Agreements were executed as part of a restructuring of
the Company, whereby the Research and Development components were made separate from the Issuer’s continuing business operations.
On February 17, 2016, the
Issuer entered into an Engagement Letter with a licensed Financial Investment Firm in Tel Aviv, Israel. As part of that Agreement,
the firm shall use its best efforts to invest funds into the company, and as part of that contract, a central condition was the
return of the previously removed High Throughput Screening IP and the Israel Subsidiary Grin Ultra, Ltd., per the 8-K as noted above.
As such, and as condition
to said Agreement, on February 22nd, 2016, the Company and Cannabics Inc., a Delaware Corporation, related party, and
majority holder of the Issuer did execute a Rescission Agreement, wholly rescinding the previous Agreements noted supra. As such,
all Intellectual Property, provisional patents, assigned Debts and the Company’s Subsidiary “Grin Ultra Ltd.”
are now reincorporated as part of the company.
ITEM 9.01 EXHIBITS
99.1 |
Rescission Agreement |
99.2 |
Board of Directors Resolution, Cannabics Pharmaceuticals, Inc. |
99.3 |
Board of Directors Resolution, Cannabics, Inc. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 22nd, 2016
|
|
|
Cannabics Pharmaceuticals Inc. |
|
|
|
|
|
By: /s/ Itamar Borochov |
|
Itamar Borochov, Director, CEO |
Exhibit 99.1
RESCISSION AGREEMENT
This Rescission Agreement is made this 22nd
February, 2016, by and among Cannabics Pharmaceuticals Inc., a Nevada corporation, and Cannabics Inc., Delaware Corporation;
WHEREAS, on October 7th, 2015, the
two parties executed an Intellectual Property & Subsidiary Assignment and an Assignment & Assumption of Debt & Liabilities
Agreement between them, as part of a restructuring of the Company;
WHEREAS, the parties hereto acknowledge the
certain Engagement letter between Cannabics Pharmaceuticals and a Licensed Investment Firm for funding, which would inure to their
mutual benefit;
WHEREAS, a condition within Agreement is the
return of all said IP and the Israeli Subsidiary Grin Ultra, to the exact condition as was previous to said October 7th
2015 Agreements;
WHEREAS, the parties hereto acknowledge that
a COMPLETE RESCISSION of the October 7th, 2015 transactions, arrangements is in their respective best interests, and
NOW, THEREFORE, IT IS AGREED
AS FOLLOWS:
1. | | Rescission Effective immediately upon the execution of this Agreement, the aforementioned
previous Intellectual Property & Subsidiary Assignment and an Assignment & Assumption of Debt & Liabilities Agreement
between the parties shall be deemed fully RESCINDED; and the respective benefits, liabilities or obligations imposed under or
by them shall be cancelled and made void and all described IP, assets and liabilities addressed in said Agreements shall revert
back unencumbered as of the date of this Agreement. |
2. | | Entire Agreement. All prior statements, agreements, representations and warranties,
if any, regarding the subject matter hereof, are totally superseded by and merged into this Agreement, which represents the final
and sole agreement of the parties with respect to the matters which are the subject hereof. |
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above-written.
/s/ Dr. Eyal Ballan |
/s/ Itamar Borochov |
Dr. Eyal Ballan, Director, CTO |
Itamar Borochov, President |
Cannabics Pharmaceuticals, Inc. |
Cannabics, Inc. |
Itamar Borochov, Director, CEO
Cannabics Pharmaceuticals, Inc.
Exhibit 99.2
THE BOARD OF DIRECTORS
OF
CANNABICS PHARMACEUTICALS INC.
The following is a true
copy of the resolution duly adopted by the Board of Directors of this Corporation at a special meeting, notice to this meeting
having been waived, held on this 22nd day of February, 2016
The Board of Directors which was present for
this meeting & took active part therein was:
Eyal Ballan
Itamar Borochov
WHEREAS there has been
presented to and considered by this meeting a decision to Accept the Return of all Intellectual Property and its Subsidiary Grin
Ultra Ltd., and RESCIND and cancel all Agreements relating thereto of 7th October, 2015.
NOW THEREFORE BE IT RESOLVED
that the majority of Directors having considered this matter, and having opened the floor to all those who voice a preference in
the issue and pursuant to NRS 78.320, have unanimously decided and RESOLVED that:
Per our Agreement with
a noted licensed Investment Firm, the Company shall RESCIND, terminate and cancel in its entirety that certain Intellectual Property
and Subsidiary Assignment Agreement, executed on October 7th, 2015, between the Company and CANNABICS INC., as well
as its ancillary agreements – the Assignment & Assumption of Debt & Liabilities Agreement and the Debt Cancellation
Agreement, both executed on October 7th, 2015, between the Company and CANNABICS INC; meaning that all technologies
and IP which exited the company shall be returned unencumbered.
Said Motion is hereby passed
and the corporate books, records and the Secretary shall file this Resolution in the corporate records
DATED: 22nd February, 2016
/s/ David E. Price
David E. Price, Secretary, Corp Counsel
Exhibit 99.3
THE BOARD OF DIRECTORS
OF
CANNABICS INC.
The following is a true
copy of the resolution duly adopted at this Special Meeting of the Corporation, held at Caesarea, Israel this 22nd day
of February, 2016.
The Board of Directors which was present for
this meeting & took active part therein per Del. Code Ann., tit. 8, § 211(a) was:
Eyal Ballan
Itamar Borochov
Shay Sarid
Eyal Barad
WHEREAS there has been
presented to and considered by this meeting a Motion to Return all Intellectual Property and the Subsidiary Grin Ultra Ltd., and
RESCIND and cancel all Agreements relating thereto of 7th October, 2015.
NOW THEREFORE BE IT RESOLVED
that the majority of Directors having considered this matter, and having opened the floor to all those who voice a preference in
the issue and pursuant to DGCL §142(b), have unanimously decided and RESOLVED that:
Per Cannabics Pharmaceutical’s
Agreement with a licensed Investment Firm, the Company has shall RESCIND and cancel in its entirety that certain Intellectual Property
and Subsidiary Assignment Agreement, executed on October 7th, 2015, between the Company and CANNABICS INC., as well
as its ancillary agreements – the Assignment & Assumption of Debt & Liabilities Agreement and the Debt Cancellation
Agreement, both executed on October 7th, 2015, between the Company and CANNABICS INC; meaning that all technologies
and IP which exited the company shall be returned unencumbered.
Said Motion is hereby passed
and the corporate books, records and the Company shall file this Resolution in the corporate records.
/s/ Itamar Borochov
Itamar Borochov, President
Cannabics, Inc.
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Jul 2024 to Aug 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Aug 2023 to Aug 2024